Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Beltropolis Boy who wrote (855)	1/15/1999 2:45:00 PM
From: William Partmann	Read Replies (1) \| Respond to of 1686

From Briefing: BIOGEN INC. (BGEN) 95 +4 3/4. One month after falling out of favor following the abrupt resignation of its highly respected CEO James Tobin, this biopharmaceutical company seems to be again attracting investor attention. Just prior to Christmas eve, the stock fell more than $7 points following the sudden departure of Mr. Tobin. However, latest Q4 earnings results, which were in line with Wall Street expectations, seems to have taken much of the worry over who's at the helm since Biogen delivered strong results, particularly sales of its lead drug Avonex. Biogen reported that it earned $0.54 a share as sales of its multiple-sclerosis drug continued to boost revenue growth in the period, with total revenues rising 36% to $168.4 million. The earnings report comes on the heels of the stock making a very good recovery following last month's CEO departure. For two weeks, the stock traded in a narrow range close to the $80 level before breaking out following a positive report and upgrade from Merrill Lynch which noted that Avonex sales were strong and being used by later stage multiple sclerosis patients. The latest earnings report confirms the trend noted by Merrill as company's new CEO James Vincent says that the company is well positioned to continue to impress in 1999, helped in part by the strong performance of Avonex. In fact, Mr. Vincent has set a goal of having 100,000 patients on Avonex within the next several years. It has been a remarkable turnaround for the stock, basically surging 20% in the past week and easily surpassing the previous high of $86 7/8 that prevailed just prior to Mr. Tobin's resignation. While Mr. Tobin's presence is still very much a part of the latest report, Biogen seems to be firing on all cylinders and preforming well despite the change at the top. Chart

To: Beltropolis Boy who wrote (855)	1/19/1999 10:29:00 PM
From: Beltropolis Boy	Respond to of 1686

previously on SI, i said, "according to CNBC, jim vincent is scheduled to appear during "power lunch" today (after 12p EST)." well, for the multimedia-enabled, here are the aud & vid replays (netshow and real player, respectively). ----- CNBC/Dow Jones Business Video 01/15/99 Biogen (BGEN) CEO Jim Vincent says the company's climbing stock is due to it's Multiple Sclerosis drug Avonex mktnews.nasdaq.com\\www\nasdaq\news\msnbc\1999\1\15\NASDAQ_1345_17775.htm&usymbol=BGEN&logo=True&companyname=Biogen%2C+Inc%2E